Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

EHA 2022 Conference Coverage
Avatar

EHA 2022 Tamibarotene in Combination With Ven & Aza in Previously Untreated Adult Pts Selected for RARA+ AML Who Are Ineligible for Standard Induction Therapy (SELECT-AML-1)

By EHA 2022 Conference Coverage FEATURING Eytan Stein
By EHA 2022 Conference Coverage FEATURING Eytan Stein
209 views
June 21, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

13:36
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss

Featured Video

18:11
Incyte

Appropriate Management of RPED (Retinal Pigment Epithelial Detachmen…

Feat. M. Khasawneh
Leukemia
18:42

Key Updates in AML, MDS, & MF From ASH

Memorial Sloan Kettering Cancer Center

A. Goldberg

330 views
15:23

SOHO 2023: Updates on the Role of SCT in ALL in the Era of CAR-T

SOHO 2023 Eleventh Annual Meeting

J. Park

90 views
13:15

SOHO 2023 Menin Inhibition for KMT2A-Rearranged ALL

SOHO 2023 Eleventh Annual Meeting

E. Stein

41 views
30:21

ASH 2022 Highlights on CML: Clinical Overview From iCMLf

International CML Foundation

M. Mauro

113 views
04:55

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamib…

ASH 2022 Conference Coverage

E. Stein

173 views
04:22

EHA 2022 Tamibarotene in Combination With Ven & Aza in Previously Un…

EHA 2022 Conference Coverage

E. Stein

209 views
54:58

Expert Perspectives on Treating High-Risk and R/R AML

PleXus Communications

E. Stein

142 views
04:36

Safety & Efficacy of Asciminib for Heavily Pretreated Patients With …

ecancer

M. Mauro

27 views
05:49

ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in MLL-…

ASH 2021 Conference Coverage on VuMedi

E. Stein

131 views
16:42

IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of R…

University of Miami's 2nd Biennial Miami Leukemia Symposium

E. Stein

228 views
06:19

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 an…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

344 views
07:59

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Nov…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

177 views
05:08

2019 ASH Review on Combinations or Sequences of Targeted Agents in C…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

79 views
04:52

2019 ASH Review on Venetoclax in the R/R CLL: With Additional Follow…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

32 views
08:21

2019 ASH Review on Overcoming BTKi Resistance in CLL: Era of Non-Cov…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

35 views
15:19

29 y/o Male w/ CML: Allograft vs. 3rd Line Therapy - Transplant Is A…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Mauro

17 views
15:59

New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Mauro

30 views
27:00

Acute Myeloid Leukemia - Overview of Available Novel Agents with Uni…

Indy Hematology Review

M. Tallman

1.8K views
07:46

Oral Abstract CML-044: Treatment-Free Remission (TFR) in Patients wi…

Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

M. Mauro

17 views
17:58

Front-line Strategies in Ph-negative ALL

Memorial Sloan Kettering Cancer Center

M. Geyer

178 views
13:41

Updates and Challenges in the Management of Chronic Myeloid Leukemia…

Memorial Sloan Kettering Cancer Center

M. Mauro

146 views
17:13

Multi-drug Resistant and Intolerant CML: What to Do?

Memorial Sloan Kettering Cancer Center

M. Mauro

172 views
08:42

IDH Inhibitors in AML

Memorial Sloan Kettering Cancer Center

E. Stein

169 views